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Although many drugs have inhibitory effects on platelet
function, none of them inhibits all of the mechanisms
that may be involved in the various forms of thrombosis.
Choice of suitable drugs is hampered by lack of full
knowledge concerning the reactions that make the major
contributions to the formation ofarterial thrombi at sites
of repeated vessel wall injury or on atherosclerotic le-
sions. Drugs such as aspirin that inhibit the arachidonate
pathway in platelets can only be expected to be effective
against thromboembolic events in which the generation
of thromboxane A2 plays a major part. If thrombin and
fibrin formation are dominant, oral anticoagulant agents
or heparin should be beneficial; thus, experimental evi-
dence indicates that with repeated vessel wall injury, the
formation of platelet fibrin thrombi on the vessel wall is
probably influenced more by inhibitors of thrombin gen-
eration than by the subendothelial constituents such as
collagen.
Phannacologic modification of platelet function reduces the
thromboembolic complications in a number of arterial vas-
cular disorders and in patients with prosthetic cardiovascular
devices (1-3). However, the indications for the clinical use
of antiplatelet agents are not entirely clear despite extensive
basic experimental animal and clinical studies. This uncer-
tainty is explained, at least in part. by our lack of knowledge
of the precise pathogenesis of many clinical vascular syn-
dromes, by the lack of suitable phannacologic agents for
definitive clinical testing and by the inconclusive results
obtained in some of the clinical studies. In this study, the
current pharmacologic status of antiplatelet drugs used in
clinical practice is reviewed.
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Agents like prostacyclin that raise platelet cyclic
adenosine monophosphate (AMP) levels in platelets by
stimulating adenylate cyclase are potent inhibitors of the
reaction of platelets to all aggregating and release-
inducing stimuli, but these agents are not suitable for
long-term administration. The effect of dipyridamole on
platelet cyclic AMP levels is weak, and this drug may
act through other effects on platelets or on other cells.
Indeed, several of the drugs that have been tested in
clinical trials may exert their effects through unrecog-
nized mechanisms. Many combinations of drugs have
been used to affect platelets or platelets and coagulation.
This practice has been based on the theory that because
several mechanisms may be involved in thrombus for-
mation, combinations of drugs that inhibit different
mechanisms may be beneficial.
(J Am Coil CardioI1986;8:21B-32B)
Ideally, a clinically useful, platelet-modifying drug should
be nontoxic, orally effective, have sustained action and have
good antithrombotic potency without excessive risk of ab-
normal bleeding. None of the currently available clinical
agents satisfies all these requirements. Aspirin, sulfinpyr-
azone, dipyridamole, suloctidil, ticlopidine and prostacyclin
have been the agents evaluated in clinical trials to date.
Many agents with more defined pharmacologic actions have
been synthesized for evaluation and are presently at various
stages of development.
The disorders for which antiplatelet therapy has been
studied may have quite different pathogenetic mechanisms.
Because the effects of a given drug may be different for
each pathogenetic process, it is probably inappropriate to
extrapolate the results for a given drug from one clinical
setting to another. In general, however, kinetic studies (4)
in patients using radioactively labeled platelets and fibrin-
ogen indicate that arterial thrombosis is characterized by
selective platelet consumption that can be interrupted by
some inhibitors of platelet function but not by heparin, whereas
venous thrombosis produces combined and equivalent con-
sumption of both platelets and fibrinogen that is blocked by
anticoagulant therapy but not by drugs that modify platelet
function.
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Pathways of Platelet Activation and
Their Modulation
Process of platelet adhesion and aggregation (Fig. 1).
Vascular injury with endothelial denudation exposes sub-
endothelial structures to circulating blood and induces plate-
lets to adhere to subendothelial collagen (5). The process
of platelet adhesion involves interaction of the platelet mem-
brane glycoprotein receptor GPlb, subendothelial collagen
and plasma von Willebrand factor and fibronectin (6). Plate-
let interaction with collagen leads to the release of adenosine
diphosphate (ADP) and activation of the prostaglandin
arachidonate pathway (7,8) to release thromboxane A2 • Both
ADP and thromboxane A2 recruit circulating platelets (9,10)
to change shape and aggregate with the layer of already
adherent platelets on the subendothelial surface (Fig. I). A
third pathway of platelet recruitment involves thrombin gen-
eration. Thrombin formation is produced through both ex-
trinsic and intrinsic coagulation processes at the injury site
and around the aggregating platelet mass. Although throm-
bin induces the release of both ADP and thromboxane A2 ,
more importantly, thrombin induces platelet aggregation and
release through a direct mechanism that is independent of
ADP release or the formation of thromboxane A2 (11-13).
In addition, the formation of polymerizing fibrin in close
proximity to the platelet aggregate by the action of thrombin
on fibrinogen stabilizes the aggregate through the adherence
of polymerizing fibrin to the platelet surface (14). Platelet
aggregates that are not stabilized by fibrin deaggregate read-
ily and are broken up under the force of blood flow.
IHepa rlnas~
All platelet recruitment requires the rapid expression of
the platelet-membrane complex GPllb/GPIlIa as the fibrin-
ogen receptor (6,9,15). That is, platelet-platelet aggregates
are formed through calcium-dependent fibrinogen binding
with the expressed receptor. This reaction may also be mod-
ulated by platelet alpha-granule proteins, fibronectin, von
Willebrand factor or thrombospondin (16).
Limitation of thrombus formation. Intact endothelium
actively limits thrombus formation and its extension by mul-
tiple mechanisms including I) inactivation of released ADP
(17), 2) active clearance of vasoactive amines (18), 3)
thrombin-mediated release of prostacyclin (19), 4) direct
inactivation of circulating thrombin by plasma protease in-
hibitors (20), 5) inactivation of thrombin by enhancement
of the endothelial surface thrombin-antithrombin III com-
plex formation (21), 6) thrombin complexing with throm-
bomodulin on the endothelial cell surface to activate protein
C (which reduces thrombin formation by destroying factors
Va and Villa both in plasma and bound to the platelet
surface) (22), and 7) thrombin-mediated release of tissue
plasminogen activator from intact vascular wall (23) (Fig.
2). Thus, thrombin initiates important negative feedback
mechanisms to control its own generation and extent of
effect.
Calcium-dependent platelet activation. There is in-
creasing evidence that some platelet responses occur through
calcium-regulated contractile processes (24), which are in
tum modulated by cyclic adenosine monophosphate (AMP)
(25) and prostaglandin or arachidonic acid products (26).
In general, contractile and secretory processes are thought
Figure 1. Pathways of platelet recruitment. Endo-
thelial disruption initiates the attachment of platelets
to the subendothelium through the interaction of a
platelet receptor (GPIb), subendothelial collagen and
a plasma cofactor VIII/von Willebrand factor (vWF).
Fibronectin and thrombospondin derived from plasma,
platelets and endothelium may also play roles in this
process. An unstable platelet mass forms through sev-
eral interactive but independent recruitment mecha-
nisms, including the generation of thromboxane (TX)
A2 release of dense granule, adenosine diphosphate
(AOP) and thrombin-mediated platelet activation.
Aggregation requires the rapid expression of platelet
membrane fibrinogen receptor complex (GPIIb and
GPIIIa) and calcium-dependent interplatelet bridging
by fibrinogen. Thrombin is generated locally on the
platelet surface through both extrinsic and intrinsic
pathways. Thrombin-modified factor V (factor Vm)
binds to platelets. Platelet-bound factor Vm serves as
a high affinity platelet receptor for factor Xa in the
final convetsion of prothrombin to thrombm. Thus,
the generation of thrombin initiates potent positive
feedback mechanisms on the platelet surface for ex-
plosive activation of the coagulation cascade and fi-
brin formation. f3TG = f3-thromboglobulin; FOP =
fibrin degradation products; POGF = platelet-de-
rived growth factor; PF4 = platelet factor 4.
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Figure 2. Mechanisms limiting throm-
bus extension. Intact endothelium ac-
tively resists thrombus formation. Plate-
let aggregate formation is prevented by
the endothelium despite the presence of
ADP, epinephrine or thrombin through
the inactivation of ADP, active clearance
of vasoactive amines, facilitated com-
plexing of thrombin with antithrombin III
and the explosive thrombin-mediated
synthesis and release of inhibitory POb.
These mechanisms markedly decrease the
possibility of thrombus forming in the
presence of intact endothelium. The po-
tent effects of thrombin are also actively
limited to the site of vascular injury by
plasma protease inhibitors, enhancement
of the endothelial surface of thrombin-
antithrombin III complex formation,
binding of circulating thrombin to throm-
bomodulin (a receptor of luminal surface
of the endothelial cells) thereby activating
protein C to destroy factors V and VIII
and induced release of tissue plasminogen
activator from vascular endothelium. Thus,
thrombin initiates negative feedback
mechanisms controlling its own genera-
tion. Abbreviations as in Figure I.
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to be mediated by an increase in the concentration of cy-
toplasmic calcium derived from intracellular storage sites
or from the extracellular environment. Calcium-dependent
platelet activation occurs through actomyosin-mediated con-
tractile mechanisms including pseudopod formation, aggre-
gation, release and clot retraction. It appears that the release
reaction is triggered by release of calcium from an intra-
cellular storage site, possibly the dense tubular system, into
the cytoplasm. Calcium regulation of contractile proteins in
platelets is similar to the processes of contraction in muscle.
Calcium and the calcium-binding protein calmodulin are
involved in activation of the specific enzyme myosin light
chain kinase and, hence, promotion of the interaction be-
tween platelet actin and myosin (27).
Platelet cyclic AMP. This compound inhibits both plate-
let secretion and aggregation (28). The amount of cyclic
AMP in the platelet is determined both by the activity of
membrane adenyl cyclase and by the specific phosphodi-
esterase that hydrolyzes cyclic AMP to adenosine triphos-
phate (ATP); that is, platelet cyclic AMP is increased by
agents that either increase the activity of adenyl cyclase or
decrease the activity of phosphodiesterase. The basal level
of cyclic AMP appears to modulate release and aggregation
by controlling the storage and release of calcium from plate-
let intracellular storage sites.
Role of prostaglandins. As discussed in more detail in
the first section of the symposium by Vermylen et al. (29)
(also see Fig. I and 2 in reference 29), prostaglandins (PG)
are important in the regulation of platelet activation for two
reasons (26,30). First, as mentioned, stimulated platelets
produce biologically active prostaglandins and derived sub-
stances that regulate platelet function. Second, other pros-
taglandins produced by other cells (such as PGh by vascular
cells) may either inhibit or activate platelets. Platelet stim-
ulation results in the hydrolysis of arachidonic acid from
membrane phospholipid, possibly through a calmodulin-
mediated process. Both phosphatidylinositol (through hy-
drolysis by phospholipase C) and phosphatidylcholine (through
hydrolysis by phospholipase Az) may serve as the source
of arachidonic acid. The arachidonic acid thus liberated
becomes converted by cyclooxygenase to labile prostaglan-
din endoperoxide intermediates (PGGz and PGHz), which
are potent platelet-aggregating agents, or through the Ii-
poxygenase pathway to other prostaglandin derivates. By
means of thromboxane synthetase, the most important con-
version of PGHz is to the highly labile nonprostaglandin
substance thromboxane Az, which is the most potent plate-
let-aggregating agent derived from arachidonic acid yet dis-
covered. In addition, thromboxane Az is a potent vasocon-
strictor. PGHz is also converted to several other (stable)
prostaglandins, namely, PGEz and PGFza , which do not
directly affect platelets but may potentiate aggregation by
other substances, and PGDz, which inhibits aggregation and
could play the role of a negative feedback mechanism in
regulating aggregation.
On the other hand, vascular tissue, cultured endothelial
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cells and postinjury neomtIma synthesize POlz from the
arachidonic acid pathways (26,31,32). Moreover, endo-
thelial cells can utilize POOz(Hz) derived from platelets to
synthesize POIz (33). POIz is about 30 to 40 times more
potent than POE) as an inhibitor of platelet aggregation
induced by ADP, epinephrine, collagen, thrombin and ar-
achidonic acid. Its inhibitory effects are mediated through
elevation of platelet cyclic AMP through activation of ad-
enylcyclase (34).
Finally, prostaglandins, cyclic AMP and Ca2+ interact
in a number of complex ways to enhance platelet function
(7,8,35). For example, both phospholipase Az and phos-
pholipase C are activated by Caz + , and the inhibitory effect
of cyclic AMP on platelet aggregation may act by main-
taining calcium in a bound form, thereby preventing acti-
vation of phospholipases. Thromboxane A2 also has prop-
erties resembling those of a calcium ionophore, and some
of the platelet-stimulatory effects of thromboxane Az may
be related to its ability to mobilize intracellular calcium from
storage sites.
Drug Testing
The first assessment of a new compound to test for plate-
let-inhibitory activity usually involves adding it to citrated
platelet-rich plasma in vitro and examining the effect on
aggregation and the release of granule contents in response
to such substances as ADP, epinephrine, collagen and ar-
achidonic acid. Suspensions of washed or gel-filtered plate-
lets are more suitable for tests with thrombin and also permit
experiments in the presence of physiologic concentrations
of ionized calcium and magnesium. Unfortunately, these
results have little predictability regarding antiplatelet effi-
cacy in vivo, and it is for this reason that the effects of these
agents on in vitro testing will not be addressed in detail in
this review. Thus, although many agents that strongly inhibit
aggregation and release in vitro have been identified, few
have proved useful in human patients, particularly for long-
term administration. Most of the drugs that have been used
in clinical trials were in use long before their effects on
platelets were recognized, and their value as antithrombotic
agents would not have been recognized by the type of routine
screening systems now being used. There have been no
reports of major trials of new drugs that have been designed
specifically as inhibitors of platelet function. Other in vitro
tests of platelet function of uncertain interpretation include
studies of platelet adherence to glass beads, artificial sur-
faces, collagen or subendothelium and examination of the
contribution of platelets to the acceleration of coagulation.
In vivo testing in experimental animals has a number of
advantages: 1) the drug is tested at concentrations that can
be achieved clinically, 2) active metabolites of the drug are
also assessed, 3) the time during which effective concen-
trations of the drug or its metabolites remain in the circu-
lation can be determined, and 4) side effects of the drug
may become apparent.
The most common tests of in vivo platelet function in
human beings after drug administration involve bleeding
time (36), platelet survival and turnover (37), examination
of plasma for materials released from platelets (platelet fac-
tor 4 and beta-thromboglobulin) (38) and determination of
the number of circulating platelet aggregates (39,40). In
addition, there are suggestions of platelet hypersensitivity,
circulating platelet aggregates or circulating materials re-
leased from platelets associated with clinical complications
of atherosclerosis (41). In almost all of these conditions,
administration of drugs that inhibit the arachidonate pathway
in platelets decreases their sensitivity to aggregating agents
and reduces the number of circulating platelet aggregates.
These variables, however, may be a result of the clinical
complications rather than the cause. If so, drugs that depress
the sensitivity of the platelets may have little effect on the
clinical complications.
Pharmacology of Drugs That Modify
Platelet Function
The pharmacology of the drugs that inhibit platelet func-
tion and thrombus formation will be considered in four broad
categories: I) drugs that inhibit the arachidonate pathway,
2) drugs that affect platelet cyclic AMP levels, 3) drugs that
inhibit thrombin formation and action, and 4) drugs that act
through less well defined mechanisms.
Drugs that inhibit the arachidonate pathway. Drugs
that affect this prostaglandin pathway include agents that
inhibit platelet cyclooxygenase, drugs that block the action
of phospholipases and drugs that inhibit thromboxane syn-
thetase. Because these drugs affect only thrombus formation
that is dependent on thromboxane Az, thrombus formation
that is predominately mediated by the other pathways and
stimuli (that is, thrombin) will be largely unaffected by this
class of drug.
Drugs that inhibit cyclooxygenase include the nonsteroid
anti-inflammatory drugs such as aspirin, indomethacin, ibu-
profen and many others (1-3,42). (Although the uricosuric
agent sulfinpyrazone has effects on cyclooxygenase, its an-
tithrombotic mechanism is unclear and is, therefore, dis-
cussed later.)
Aspirin and platelet function. Aspirin inhibits the second
but not the first wave of ADP-induced platelet aggregation.
Aspirin affects, in part, collagen-induced platelet aggre-
gation caused by its inhibitory effect on platelet secretion.
In addition to inhibiting the release of ADP, aspirin in vitro
and in vivo inhibits the collagen-induced release of ATP,
serotonin and platelet antiheparin activity (platelet factor 4).
Similar results have been obtained with epinephrine-induced
aggregation. The effects of aspirin on thrombin-induced
lACC Vol S. No 6
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aggregation and secretion are dose-related. Inhibition occurs
at low but not high concentrations of thrombin (43). Finally,
the inhibitory effects of aspirin on platelet aggregation to
different agents are detected for 4 to 7 days after a single
oral dose when salicylate is no longer detectable in the
blood. This period of inhibition reflects an irreversible effect
of aspirin on the platelet.
Aspirin irreversibly acetylates the cyclooxygenase in
platelets (44). Because platelets are unable to synthesize
new enzyme to replace that which has been inactivated, it
is not until new platelets enter the circulation that platelet
function is restored. However, aspirin also acts on mega-
karyocyte cyclooxygenase. This is shown by the finding that
human platelets harvested at times up to 48 hours after
administration of aspirin cannot be acetylated in vitro with
radiolabeled aspirin (45), and also by direct experiments
with megakaryocytes that indicate that aspirin administra-
tion abolishes their ability to synthesize prostaglandins (46).
The long-term administration of I mg/kg of aspirin once a
day effectively inhibits platelet cyclooxygenase and throm-
boxane A~ formation in humans.
In contrast, aspirin inhibition of the cyclooxygenase of
the cells of the vessel wall is not irreversible because these
cells synthesize new cyclooxygenase. Regeneration of the
ability of cultured human endothelial cells from umbilical
veins to synthesize PGI~ requires many hours (47). Indeed,
long-term administration of I mg/kg of aspirin once a day
will also effectively inhibit vascular cyclooxygenase and
prostaglandin production in humans (48). Thus, the notion
that low dose, infrequently administered aspirin exerts its
antithrombotic effects by preferentially sparing vascular
prostacyclin production may not be correct. Furthermore,
high doses of aspirin over prolonged periods to patients with
rheumatoid arthritis may decrease thrombosis despite in-
hibition of PGI~ production (49). Earlier data concerning
the low incidence of myocardial infarction as a cause of
death of patients with rheumatoid arthritis who consumed
large amounts of aspirin also support this view (50).
Under physiologic conditions of flow and protein con-
centration and hematocrit, aspirin does not inhibit adherence
of the initial layer of platelets to the subendothelium (51 ,52).
Aspirin and indomethacin also do not inhibit the release of
amine storage granule contents from platelets that adhere
directly to collagen or the subendothelium (53), and released
ADP and serotonin from these platelets contribute to throm-
bus formation in the presence of the cyclooxygenase inhib-
itors. Because aspirin does not inhibit release of platelet-
derived growth factor from the alpha granules of the ad-
herent platelets, it is not surprising that these drugs do not
prevent smooth muscle cell proliferation in response to ves-
sel damage (54). However, these drugs may inhibit platelet
aggregate formation on the layer of adherent platelets (52),
presumably by blocking thromboxane A~ release.
In some experimental animal studies, aspirin has par-
tially inhibited thrombus formation. In other studies no sig-
nificant effects have been observed and, in a few, aspirin
has been reported to potentiate thrombus formation (55).
The last effect has been attributed to aspirin inhibiting PGI~
production by the vessel wall.
Aspirin in unstable angina and ischemia. In the myo-
cardial and cerebral circulations, platelet aggregate forma-
tion and, perhaps, associated vasospasm (related to the re-
lease of thromboxane A2 or platelet-derived growth factor
[56,57]) may lead to the acute coronary syndromes (that is,
unstable angina, myocardial infarction, arrhythmia-related
sudden death) or transient ischemic attacks, respectively.
In dogs with experimentally stenosed coronary arteries, as-
pirin inhibits the formation of platelet plugs and the occur-
rence of fatal arrhythmias (58). Studies (59,60) with isch-
emic dog and cat myocardium have shown that aspirin can
prevent ventricular fibrillation caused by ischemia. The ben-
eficial effects of aspirin in patients with unstable angina or
transient ischemic attacks and in the experimental prepa-
rations just referred to, may be related not only to its ability
to inhibit platelet aggregation, but also to the inhibition of
release of thromboxane A~ and platelet-derived growth fac-
tor, preventing vasoconstriction so that thromboemboli do
not readily lodge and persist in the microcirculation.
Aspirin and thromboembolism. Aspirin has been shown
to be clinically effective in reducing thromboembolic com-
plications of artificial heart valves in one study (61), throm-
botic occlusion of arteriovenous cannulas in uremic patients
(62), stroke and death in patients with transient ischemic
attack (63), myocardial infarction in men with unstable an-
gina (64,65), and, possibly, the occlusion of saphenous vein
coronary artery bypass grafts (66). It may be important in
this context to note that an additional hemostatic abnormality
was associated with the beneficial effect of aspirin in the
studies of artificial heart valves (oral anticoagulation) and
arteriovenous cannulas (platelet dysfunction in uremic pa-
tients treated with long-term hemodialysis). The reported
antithrombotic effect of aspirin in patients undergoing sa-
phenous vein coronary artery bypass surgery is provisional
in that the study involved a relatively small number of pa-
tients with an unusually high frequency of graft occlusion
in the control group. Thus, aspirin may exert limited an-
tithrombotic effects unless it is used in association with
another antithrombotic drug or perturbation of the hemo-
static mechanism.
Regarding aspirin dose, the beneficial effects of low doses
of aspirin (100 to 150 mg/day) reported to prevent throm-
bosis in saphenous vein aortocoronary bypass grafts and
arteriovenous shunts must be considered to be provisional
because, as already mentioned, the former study requires
confirmation because of questions regarding the control group,
and the conclusions of the latter study may not be extrap-
olated to other clinical settings because of the associated
platelet dysfunction in those patients undergoing long-term
268 HARKER AND FUSTER
PHARMACOLOGY OF PLATELET INHIBITORS
JACC Vol X. No 6
December I'!X6 21B-32B
hemodialysis. On the other hand, there are clinical reports
of high dose-dependent antithrombotic effects of aspirin. In
this context, recent studies (67) in experimental throm-
boembolism indicate that aspirin has antithrombotic effects
that are independent of its effect on cyclooxygenase and
that these effects occur at high doses.
Nonsteroid anti-inflammatory drugs. Other nonsteroid
anti-inflammatory drugs also inhibit platelet activation through
inhibition of platelet cyclooxygenase (67). However, these
agents differ in potency and duration of action because they
inhibit competitively. In addition, some of these drugs may
have other effects on platelets besides inhibiting cyclo-
oxygenase. For example, indomethacin may inhibit phos-
pholipase activation. At equimolar concentrations, meclofe-
namic acid, aspirin and indomethacin and ibuprofen were
the most active, whereas phenylbutazone was a relatively
weak inhibitor (68).
Other agents. Drugs that affect the generation of ara-
chidonate from the cell membrane have been considered to
be inhibitors of phospholipase Az; they include the anti-
malarial drug quinacrine hydrochloride (mepacrine hydro-
chloride) and some of the steroid anti-inflammatory drugs.
None of these agents has been shown to have clinically
useful antithrombotic effects in humans (42).
Inhibitors that block thromboxane synthetase include im-
idazole and its derivatives. Although a number of these
compounds have been synthesized and have undergone test-
ing in animal models and human subjects (69), none of
these agents has been shown to prevent thrombosis in hu-
mans.
Drugs that increase platelet cyclic AMP levels. When
the cyclic AMP level in platelets is elevated, many platelet
functions are inhibited (42). Platelet cyclic AMP is increased
by agents that stimulate adenylate cyclase and, to a lesser
extent, by drugs that inhibit platelet phosphodiesterase (79)
and, thus, prevent the breakdown of cyclic AMP in platelets
(42). Adenylate cyclase is stimulated by PGlz, PGFz and
PGE!. The combination of PGIz or PGE, with a phospho-
diesterase inhibitor such as dipyridamole or theophylline
strongly inhibits platelet functions (71,72).
PGE1 and PGIz. Agents that increase cyclic AMP levels
diminish rabbit platelet adherence to damaged vessel walls
(72), inhibit platelet aggregation induced by all stimuli and
inhibit the release of platelet granule contents induced by
all stimuli (26,42,74). When cyclic AMP levels are raised,
the change in platelet shape in response to aggregating and
release-inducing agents is also inhibited. This prevents platelet
membrane sites involved in the intrinsic coagulation path-
way from becoming available to accelerate the generation
of thrombin on the platelet surface. Agents such as PGE 1
or PGIz, when given in high doses, have been shown to be
strong inhibitors of platelet aggregation, thrombus formation
and their consequences under a variety of situations in hu-
mans and experimental animals (75-80). PGIz is the most
potent inhibitor of platelet aggregation thus far described,
and it is 30 to 40 times more potent than PGE, in inhibiting
platelet aggregation by ADP. The duration of these effects
in vivo is very short; they disappear within 30 minutes of
dosing. PGh is a strong dilator in several vascular beds such
as those of the heart, kidney, mesenteric and skeletal muscle
(81,82). Intravenous infusion of relatively small amounts
(5 ng/kg per min) of PGlz in human patients produces vaso-
dilation of peripheral blood vessels in the head, neck and
palms, a decrease in diastolic but not systolic blood pressure
and an increase in heart rate (83). Platelet aggregation in
response to ADP and the number of circulating aggregates
decrease during PGIz infusion, while the bleeding time in-
creases. One hour after termination of the infusion, the
responsiveness of the platelets to ADP returns to normal.
Dipyridamole. Dipyridamole is another platelet-inhibitor
drug. It has been proposed that it acts to elevate platelet
cyclic AMP by both blocking platelet phosphodiesterase-
dependent breakdown and increasing cyclic formation by
PGIrmediated stimulation of platelet adenylate cyclase (72).
It seems more likely that an increase in blood adenosine
levels may be involved because dipyridamole is a potent
inhibitor of vascular and erythrocyte adenosine uptake (84,85)
and produces an elevation in plasma adenosine levels (86).
The higher plasma concentrations of adenosine could me-
diate the inhibition of platelet reactivity by stimulating plate-
let adenylate cyclase activity (87). For example, 10 fLM of
dipyridamole in vivo markedly inhibits the uptake of aden-
osine by endothelial cells and produces potent antiaggre-
gating activity that is not blocked by aspirin (that is, in the
absence of prostacyclin). The vasodilating effects of dipyr-
idamole also appear to be related to the elevation of plasma
adenosine levels. Indeed, vasodilation may account for its
actions in some experimental situations in which it has been
shown to be beneficial (88).
Dipyridamole, when given experimentally at a very high
dose, does inhibit platelet adherence to collagen (89) and
the subendothelium (90), but most importantly, when given
at a dose more comparable with that used in humans, di-
pyridamole inhibits platelet activation over artificial surfaces
(67,91). Indeed, the capacity of dipyridamole to decrease
experimental thromboembolism in a dose-dependent fashion
correlates well with its ability to normalize platelet survival
in patients with artificial heart valves (92,93) and arterio-
venous cannulas (94) and its efficacy in preventing throm-
boembolism in patients with prosthetic heart valves (95).
Moreover, the dose (10 mg/kg per day) and resulting blood
levels that produce complete interruption of experimental
thromboembolism at prosthetic surfaces are in reasonable
accord with the dose (5 to 7 mg/kg per day) reported to
normalize platelet survival (92,94,96) and prevent throm-
boembolism in patients with artificial heart valves.
JACC Vol. 8, No 6
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Aspirin potentiates the efficacy of dipyridamole in ex-
perimental thromboembolism on prosthetic surfaces (67).
Moreover, the full potentiation depends on administering a
relatively high dose of aspirin simultaneously with every
dose of dipyridamole (20 mg/kg per day). These results in
baboons are in accord with the capacity of the combination
of aspirin and dipyridamole to prolong platelet survival in
patients with Dacron vascular grafts (96). On the other hand,
the data regarding the beneficial effects on platelet survival
and thromboembolism of the combination of aspirin and
dipyridamole in biologic surfaces such as in coronary artery
atherosclerosis (97-99), renal microvascular disease (100)
and saphenous vein bypass grafting (10 I, 102) has raised
the possibility of aspirin being the main effective compo-
nent. That is, in four other different trials (103-106), the
combination of aspirin and dipyridamole was as effective
as aspirin alone; in only one trial (107) addressing the rate
of progression of peripheral vascular disease did this com-
bination appear to be more effective than aspirin alone, but
this remains to be confirmed.
The mechanism whereby aspirin potentiates the anti-
thrombotic activity of dipyridamole. particularly in exper-
imental prosthetic surfaces. is not: I) mediated through as-
pirin's conversion to salicyclic acid; 2) due to altered
pharmacokinetic results; or 3) dependent on inhibition of
the cyclooxygenase-thromboxane Az pathway since the spe-
cific blockage of thromboxane Az formation with dazoxiben
does not by itself produce detectable antithrombotic activity
or potentiation of dipyridamole's antithrombotic activity (67),
Drugs that inhibit thrombin. The effects of thrombin
on platelets and' fibrin formation can be prevented by in-
hibiting its action with heparin. Heparin, through its effect
on antithrombin III, also inhibits other serine proteases
produced during activation of the coagulation cascade, such
as factors IXa, Xa and XIa (108).
Heparin. Reports of the effects of heparin on platelet
reactions are complex and contradictory (109,110) perhaps,
in part, because of the variability among different com-
mercially available heparin preparations. In vitro, heparin
prevents the effects of thrombin on platelets, but may po-
tentiate or inhibit aggregation and release induced by other
aggregating agents (109,110). It may itself cause platelet
aggregation.
It is now recognized that heparin is heterogeneous with
respect to its molecular size and its affinity for antithrombin
III (111,112). More than 60% of some commercial forms
of heparin are practically inactive as an anticoagulant. In
one study (109), heparin induced platelet aggregation in
citrated platelet-rich plasma, Fractions of high molecular
weight (approximately 20,000 daltons) were more reactive
with platelets than were fractions of low molecular weight
(approximately 7,000 daltons). These findings raise the pos-
sibility that it may be feasible to select fractions of low
molecular weight and high antithrombin III activity for an-
tithrombotic therapy without the undesirable effects of un-
fractionated heparin on platelets.
Heparin combined with prostaglandins. Two observa-
tions should be considered in the relation between the effects
of heparin and PGIz on platelet function. In the presence of
PGlz, the inhibitory effect of heparin on coagulation should
be enhanced (113). On the other hand, heparin has been
shown to inhibit the activation of adenylate cyclase by PGlz
(114). Thus, a combination of heparin with one of these
prostaglandins might prove beneficial in preventing the for-
mation of thrombi to which the coagulation pathway makes
a major contribution, but might be less useful if platelet
aggregation in response to collagen, ADP and thromboxane
Az has a dominant role and PGlz acts in a regulatory role.
Overall, when well defined anticoagulant fractions of hep-
arin become available for more extensive testing, it will be
important to reassess the antiplatelet effects of heparin in a
variety of experimental and clinical situations.
An alternative strategy being developed to block throm-
bin-mediated platelet thrombus formation involves the syn-
thesis of peptides that show specificity for the inhibition of
thrombin (115-117). A number of these agents have been
studied in vitro and in experimental animals. No clinical
experience is available.
Agents that inhibit platelet function by other mech-
anisms. Many other agents have been shown to inhibit
platelet reactions and thrombus formation, although their
mechanisms of action remain to be defined (1-3,42).
Suljinpyrazone. Sulfinpyrazone inhibits platelet aggre-
gation and secretion in vitro, but at concentrations higher
than that achieved after standard clinical doses (42). Inhi-
bition of platelet aggregation and secretion after oral admin-
istration of high doses of sulfinpyrazone has also been re-
ported (118). However, the concentration of collagen used
in performing in vitro tests is critical in demonstrating an
inhibitory effect of sulfinpyrazone after oral administration
of the drug in humans (119). Although it has been suggested
that sulfinpyrazone, in contrast to aspirin, is a competitive
inhibitor of platelet cyclooxygenase, present data suggest
that other mechanisms are more relevant in vivo (42,67).
The inhibitory effects of sulfinpyrazone on collagen-induced
aggregation in rabbits has persisted for many hours after the
drug was cleared from the blood. This prolonged inhibitory
effect has been attributed to mediated drug metabolites in
plasma (120). Sulfinpyrazone has also been found to inhibit
the formation of thrombi on subendothelium (121) and to
protect endothelium from chemical injury in vitro and pos-
sibly in vivo (122). No mechanism has been identified for
this postulated endothelial protective effect. In addition, a
dose-dependent inhibition by sulfinpyrazone of experimen-
tal thromboembolism has been reported (67) that correlates
with its capacity to normalize platelet survival in patients
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with artificial heart valves (123) and with its ability to reduce
thrombotic events in patients with arteriovenous cannulas
(124). Experimentally on prosthetic surfaces, aspirin also
potentiates this antithrombotic effect of sulfinpyrazone, with
a maximal effect at 20 mg/kg per day, the same dose found
to optimally potentiate dipyridamole (67). These results with
sulfinpyrazone on prosthetic surfaces have been more con-
sistent than with biologic surfaces. Thus, despite a beneficial
trend in decreasing vascular events after myocardial infarc-
tion (125) and saphenous vein coronary artery bypass (126),
the results were negative in the Canadian stroke study (63)
and in the Canadian unstable angina study (65).
Ticlopidine. Ticlopidine is unusual in two respects: 1)
its effects are only manifest 24 to 48 hours after adminis-
tration, but they last for several days after the drug is stopped;
and 2) it is an inhibitor of the primary phase of ADP-induced
aggregation (127,128). It also inhibits aggregation and re-
lease induced by collagen, epinephrine, arachidonic acid
and thrombin, prolongs the bleeding time, prolongs short-
ened platelet survival (129) and inhibits intimal proliferation
(130) in the rabbit aorta from which the endothelium has
been removed. As well as being an inhibitor of platelet
reactions in its own right, ticlopidine has been shown to
enhance the inhibitory effect of PGh on platelets (13!).
Thus, of the antiplatelet drugs currently available for clinical
investigation, ticlopidine is one of the most potent and has
several important theoretical advantages over existing drugs.
Ticlopidine is chemically unrelated to other antiplatelet drugs
and appears to have a unique, albeit unknown, mechanism
of action. It is neither a prostaglandin synthesis inhibitor
nor a cyclic AMP-phosphodiesterase inhibitor. There are
data that indicate that ticiopidine may act on the platelet
membrane to alter its reactivity to activating stimuli (128).
Clinical evaluation of this drug is underway in a number of
European and American trials.
Antibiotics. In high doses, carbenicillin and penicillin
produce a bleeding tendency in patients (132). Studies with
human volunteers have shown that these antibiotics also
prolong the bleeding time and inhibit platelet aggregation
induced by a variety of agents. The drugs also inhibit platelet
activation in vitro at concentrations greater than those ob-
tained in vivo (133). Similar findings have been described
for ticarcillin. In vitro studies suggest that these drugs in-
terfere with the binding of substances such as ADP, epi-
nephrine and factor VIII/von Willebrand factor with their
specific receptors on the platelet membrane, perhaps as a
result of properties that permit them to bind to membrane
proteins or, as shown with artificial phospholipid bilayers,
to platelet membrane lipids (134). The inhibitory effects in
vitro are observed immediately, but the prolongation of the
bleeding time occurs after 12 to 24 hours of parenteral
administration (132,133). Therefore, either a metabolite or
prolonged contact of platelets with lower concentrations of
the antibiotics may account for the inhibition of platelet
activation observed in subjects who received the drugs (134).
Although these antibiotics appear to have platelet-inhibiting
effects, no studies have been performed demonstrating that
they prevent clinical thrombosis.
Dextran infusions. Dextran of a molecular weight of
65,000 to 80,000 daltons produces a prolonged bleeding
time after patients receive one or more liters (135-137).
The inhibitory effects of dextran infusions on platelet func-
tion are dose-related and are more pronounced with dextran
of high molecular weight. The finding that platelets absorb
dextran, with resultant changes in electrophoretic mobility,
suggests that the inhibitory effect of dextran on platelet
function might be due to some alteration of platelet mem-
brane function. Other findings suggest that dextran may
temporarily impair platelet function by interfering with the
factor VIII/von Willebrand factor complex (138). Anti-
thrombotic effects of dextran have been shown by experi-
mental and clinical studies (3,42).
Suloctidil. This compound, originally introduced to pre-
vent vasospasm at high concentrations, has been reported
to have a weak effect on platelet aggregation and secretion
(139). Although it has been reported to be antithrombotic
in some thrombotic models and to prolong shortened platelet
survival time in patients with artificial heart valves (140,141),
suloctidil is ineffective in the secondary prevention of stroke
(142) and in experimental arterial thromboembolism (143).
Vitamin E. This agent inhibits collagen-induced aggre-
gation and the second phase of aggregation induced by ADP
or epinephrine in citrated human platelet-rich plasma (144).
It has been suggested that vitamin E may prevent the internal
calcium flux that mediates internal platelet contraction and
secretion induced by aggregating and release-inducing agents
(145). However. the clinical antithrombotic usefulness of
vitamin E remains unproved.
Other drugs. A variety of other drugs have been reported
to have in vitro antiplatelet effects (1-3,42): calcium chan-
nel blockers, clofibrate and halofenate, furosemide and other
diuretic drugs, serotonin antagonists, anesthetics, pheno-
thiazines, tricyclic antidepressants, antihistamines, pro-
pranolol and other beta-adrenergic blocking agents, glyceryl
guaiacolate, furadantin, monoamine oxidase inhibitors, pyr-
idinal carbamate, hydroxychloroquine, alcohol, pyrizadine
derivates, pyridoxal phosphate and chlortetracycline. Clin-
ically useful antithrombotic effects have not been demon-
strated using any of these agents.
Summary of Drug Effects
The principal antithrombotic effects of those drugs ad-
equately evaluated are summarized as follows:
Aspirin. This nonsteroid anti-inflammatory agent po-
tently and irreversibly inactivates platelet cyclooxygenase
by acetylation. Although all of aspirin's antithrombotic ef-
fects have been attributed to this blockade of thromboxane
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A2 formation by platelets, there is evidence for anti throm-
botic effects independent of its inactivation of cyclooxy-
genase. At present, there is intense interest in aspirin therapy
for vascular disease.
Aspirin has been shown in well designed clinical trials
to be beneficial in at least five and possibly six clinical
settings: I) reduction of thromboembolic complications as-
sociated with artificial heart valves; 2) prevention of stroke
and death in patients with transient ischemic attacks; 3)
decrease in thrombotic occlusion of arteriovenous Silastic
cannulas in uremic patients undergoing hemodialysis; 4)
reduction in myocardial infarction and cardiac death in pa-
tients with unstable angina; 5) probable effect in the sec-
ondary prevention of myocardial infarction; and 6) possible
increase in the patency of saphenous vein coronary bypass
grafts. These reported benefits of aspirin require some com-
ment. First, the antithrombotic effects of aspirin in patients
with prosthetic mitral valves are evident in association with
oral anticoagulant therapy, and this combination is associ-
ated with an unacceptably high frequency of gastrointestinal
bleeding. Second, the capacity of aspirin in low doses to
reduce the thrombotic complications of arteriovenous can-
nulas was shown in patients undergoing long-term hemo-
dialysis and, thus, associated with significant platelet dys-
function. It cannot be assumed that a similar dose would
be antithrombotic in the absence of associated platelet dys-
function.
Sulfinpyrazone. This urocosuric agent has weak anti-
inflammatory properties. The mechanism of antithrombotic
action remains to be defined. Sulfinpyrazone reduces arte-
riovenous cannula occlusion and early coronary artery sa-
phenous vein graft occlusion. Since the claimed benefit in
reducing mortality in the secondary prevention of myo-
cardial infarction remains controversial, no recommenda-
tions can be made regarding that possible indication. The
reports that it may also decrease thromboembolism in pa-
tients with artificial heart valves require confirmation.
Dipyridamole. This agent, a coronary vasodilator with
weak inhibitory effects on phosphodiesterase activity, ap-
pears to increase inhibitory cyclic AMP levels in platelets
by elevating blood adenosine levels through the blockade
of adenosine uptake by red blood cells and vascular wall
cells. Experimentally, on artificial surfaces, aspirin poten-
tiates the antithrombotic effects of dipyridamole by mech-
anisms independent of platelet inactivation of platelet cy-
clooxygenase. Dipyridamole decreases thromboembolism
in patients with artificial heart valves (in combination with
anticoagulants). Dipyridamole in association with aspirin
may be more effective than aspirin alone in reducing the
progression of peripheral vascular disease, but this remains
to be confirmed. When used in combination with aspirin,
it has been shown to decrease coronary mortality and non-
fatal myocardial infarction in patients who have previously
sustained a myocardial infarction, to reduce both early and
late coronary artery saphenous vein graft occlusion and to
preserve renal function in patients with membranoprolifer-
ative glomerulonephritis. However, the benefit of adding
dipyridamole to aspirin in these latter settings of biologic
surfaces remains to be established.
Ticlopidine. This agent exhibits global antiplatelet ac-
tivity of prolonged duration through some apparently novel
mechanism of action. The fact that ticlopidine does not
inhibit prostacyclin synthesis in the arterial wall, but can
still inhibit aggregation induced by thromboxane Az and
prostaglandin endoperoxide, gives it a theoretical advantage
over aspirin. A number of important weB designed multi-
center trials are in progress. These trials should determine
the ultimate clinical role of ticlopidine.
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